Lack of ocular side effects after 2 years of topical steroids for allergic rhinitis

Journal of Pediatric Ophthalmology and Strabismus

Volumn 48, Issue 5, 2011, Pages 311-317

  Ozkaya, Emin ^a   Ozsutcu, Mustafa ^a   Mete, Fatih ^a  

^a VAKIF GUREBA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; IMMUNOGLOBULIN E;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ALLERGIC RHINITIS; ARTICLE; CATARACT; CHILD; CONTROLLED STUDY; CORNEA DISEASE; CORRELATION ANALYSIS; DRY EYE; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATOMETRY; MAJOR CLINICAL STUDY; MALE; SCHIRMER TEST; SCHOOL CHILD; SKIN TEST; TREATMENT DURATION; VISUAL ACUITY;

ADMINISTRATION, INTRANASAL; ADOLESCENT; BUDESONIDE; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; EYE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RHINITIS, ALLERGIC, PERENNIAL;

EID: 83455246924     PISSN: 01913913     EISSN: None     Source Type: Journal    
DOI: 10.3928/01913913-20101018-03     Document Type: Article

References (39)

1. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108:S2-S8.
2. Ibiapina Cda C, Sarinho ES, Camargos PA, Andrade CR, Cruz Filho AA. Allergic rhinitis: epidemiological aspects, diagnosis and treatment. J Bras Pneumol. 2008;34:230-240.
3. Bloebaum RM, Grant JA, Sur S. Immunomodulation: the future of allergy and asthma treatment. Curr Opin Allergy Clin Immunol. 2004;41:63-67.
4. Blaiss MS. Safety consideration of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc. 2007;28:145-152.
5. Baena-Cagnani CE. Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf. 2004;27:883-898.
6. Rizzo MC, Solé D, Naspitz CK. Corticosteroids (inhaled and/or intranasal) in the treatment of respiratory allergy in children: safety vs. efficacy. Allergol Immunopathol (Madr). 2007;35:197-208.
7. Passalacqua G, Albano M, Canonica GW, et al. Inhaled and nasal corticosteroids: safety aspects. Allergy. 2000;55:16-33.
8. Juniper EF, Stahl E, Doty RL, et al. Clinical outcomes and ad verse effect monitoring in allergic rhinitis. J Allergy Clin Immunol. 2005;115:S390-S413.
9. Trangsrud AJ, Whitaker AL, Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy. 2002;22:1458-1467.
10. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112:S1-S40.
11. Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician's perception. Chest. 2006;130:S41-S53.
12. Bielory L, Blaiss M, Fineman SM, et al. Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2006;96:514-525.
13. Brozek JL, Baena-Cagnani CE, Bonini S, et al. Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy. 2008;63:38-46.
14. Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol. 2001;108:S54-S58.
15. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy. 2007;62:1071-1077.
16. Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, Arrieta-Gomez JR, Astorga del Toro R, Bravo-Escobar G. Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg. 2004;130:187-191.
17. Passalacqua G, Compalati E, Canonica GW. Investigational drugs for allergic rhinitis. Expert Opin Investig Drugs. 2010;19:93-103.
18. Baroody FM, Shenaq D, DeTineo M, Wang J, Naclerio RM. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol. 2009;123:1342-1348.
19. Knutsson U, Stierna P, Marcus C, Carlstedt-Duke J, Carlström K, Brönnegård M. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol. 1995;144:300-310.
20. Szefler SJ. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001;108:S26-S31.
21. Black RL, Oglesby RB, Von Sallmann L, Bunim JJ. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA. 1960;174:166-171.
22. Agertoft L, Larsen FE, Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J. 1998;12:130-135.
23. Pelkonen A, Kari O, Selroos O, Nikander K, Haahtela T, Turpeinen M. Ophthalmologic findings in children with asthma receiving inhaled budesonide. J Allergy Clin Immunol. 2008;122:832-834.
24. Gawchik SM, Saccar CL. A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis. Drug Saf. 2000;23:309-322.
25. Banov CH, Woehler TR, LaForce CF, et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy. 1994;73:240-246.
26. Öztürk F, Yücetürk AV, Kurt E, Ünlü HH, Ilker SS. Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids. Ear Nose Throat J. 1998;77:846-851.
27. Kewley GD. Possible association between beclomethasone dipropionate aerosol and cataracts. Aust Paediatr J. 1980;16:117-118.
28. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8-14.
29. Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology. 2001;12:229-234.
30. Toogood JH, Markov AE, Baskerville J, Dyson C. Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. J Allergy Clin Immunol. 1993;91:571-579.
31. Castrow FF 2nd. Atopic cataracts versus steroid cataracts. J Am Acad Dermatol. 1981;5:64-66.
32. Derby L, Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol. 2000;105:912-916.
33. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol. 2008;100:272-279.
34. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997;277:722-727.
35. Spiliotopoulos C, Mastronikolis NS, Petropoulos IK, Mela EK, Goumas PD, Gartaganis SP. The effect of nasal steroid administration on intraocular pressure. Ear Nose Throat J. 2007;86:394-395.
36. Bielory L, Georges G, Gross G. Treating the ocular symptoms of seasonal allergic rhinitis with triamcinolone acetonide aqueous nasal spray. Ann Allergy Asthma Immunol. 2009;103:80-81.
37. Kaya V, Karakaya M, Utine CA, Albayrak S, Oge OF, Yilmaz OF. Evaluation of the corneal topographic characteristics of keratoconus with orbscan II in patients with and without atopy. Cornea. 2007;26:945-948.
38. Barreto J Jr, Netto MV, Santo RM, José NK, Bechara SJ. Slitscanning topography in vernal keratoconjunctivitis. Am J Ophthalmol. 2007;143:250-254.
39. Möller C, Ahlström H, Henricson KA, Malmqvist LA, Akerlund A, Hildebrand H. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy. 2003;33;816-822.